Celldex Therapeutics Inc CLDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
-
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
-
Celldex Therapeutics to Present at Upcoming Investor Conferences
-
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
-
Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
-
Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions
Trading Information
- Previous Close Price
- $32.86
- Day Range
- $31.22–33.32
- 52-Week Range
- $22.11–53.18
- Bid/Ask
- $30.13 / $33.21
- Market Cap
- $2.20 Bil
- Volume/Avg
- 1.4 Mil / 961,989
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 224.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 160
- Website
- https://www.celldex.com
Comparables
Valuation
|
Metric
|
CLDX
|
ARTV
|
CGON
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.70 | — | 4.57 |
Price/Sales | 224.17 | 3.88 | 252.33 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CLDX
|
ARTV
|
CGON
|
|---|---|---|---|
Quick Ratio | 29.06 | 4.43 | 46.66 |
Current Ratio | 29.36 | 4.59 | 47.57 |
Interest Coverage | — | — | — |
Quick Ratio
CLDX
ARTV
CGON
Profitability
|
Metric
|
CLDX
|
ARTV
|
CGON
|
|---|---|---|---|
Return on Assets (Normalized) | −19.66% | −16.21% | −15.24% |
Return on Equity (Normalized) | −20.83% | — | −26.61% |
Return on Invested Capital (Normalized) | −20.72% | — | −25.60% |
Return on Assets
CLDX
ARTV
CGON
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hgzbmxswb | Msvp | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ftyhhrd | Djybqpp | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Spldkwkcl | Cbhfpbj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vvsqbftlc | Wzxyxk | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Mqvnbzjnd | Klbkv | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kmxvgdlg | Xbtv | $28.1 Bil | |||
| Moderna Inc
MRNA
| Dnkgbxch | Ggs | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Pyfwfgvsq | Gkjm | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jwbgtsl | Lgblhjb | $13.4 Bil | |||
| Incyte Corp
INCY
| Nfgrmhcrl | Prxvs | $12.7 Bil |
United States